Foresight Diagnostics and Partners to Present New Data on Ultra-sensitive Minimal Residual Disease Detection and Clinical Trial Progress at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BOULDER, Colo., May 1, 2025 /PRNewswire/ -- Foresight Diagnostics, Inc. ("Foresight"), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced that new data in newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 30 - June 3, 2025, in Chicago, Illinois.

The company will deliver an oral presentation in collaboration with Amsterdam University Medical Centers (Amsterdam UMC), highlighting new validation results using Foresight CLARITY™ MRD, along with a trial-in-progress poster on the SHORTEN-ctDNA clinical trial in partnership with Columbia University. Foresight CLARITY's ultra-sensitive MRD detection is powered by Foresight's proprietary PhasED-Seq™ technology, which delivers an analytical sensitivity of less than 1 part per million in B-cell lymphoma.¹

"These presentations mark important clinical validation milestones for our Foresight CLARITY platform," said Dr. David Kurtz, Chief Medical Officer at Foresight Diagnostics. "The presentations demonstrate that our ultra-sensitive MRD detection at the end of first-line therapy identifies DLBCL patients at significantly higher risk of relapse. Meanwhile, the SHORTEN-ctDNA study is exploring how MRD testing can inform de-escalation strategies in newly diagnosed patients. Our goal is to provide oncologists with actionable data that meaningfully improves treatment decisions and patient outcomes."

Further information about the presentations is below:

Oral Presentation Details:

• Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial
• Presenter: Steven Wang, MD, PhD (Amsterdam UMC)
• Session: Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
• Time: Friday, May 30 | 2:45 – 5:45 p.m. CDT
• Location: Room S100a or live stream for virtual attendees
• Abstract number: 7000

Poster Presentation Details:

• Title: Sequencing-guided Chemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA (NCT06693830)
• Presenter: Stephanie Meek, PhD (Foresight Diagnostics)
• Session: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
• Time: Sunday, June 1 | 9:00 a.m. – 12:00 p.m. CDT
• Abstract number: TPS7096
• Poster Board number: 272a

In addition, the Foresight Diagnostics booth is located in the Innovation Hub #3. To learn more about Foresight's activities at ASCO, please visit the ASCO event page on our website.

¹Boehm, et al. 2024

About Foresight Diagnostics

Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-certified laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on X, LinkedIn, and Bluesky. Foresight CLARITY™ IUO is an investigational device. Limited by United States Law to investigational use.

SOURCE Foresight Diagnostics, Inc.